An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 664-673

  Pollack, Margaret ^a   Heugel, Judson ^a,b   Xie, Hu ^a   Leisenring, Wendy ^a   Storek, Jan ^c   Young, Jo Anne ^d   Kukreja, Manisha ^e   Gress, Ronald ^f   Tomblyn, Marcie ^g   Boeckh, Michael ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

^e CIBMTR   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antifungal porphylaxis; Cytomegalovirus disease; Hematopoietic stem cell transplanation; Herpesvirus infection

Indexed keywords

ACICLOVIR; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; VALACICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BLOOD; CYTOMEGALOVIRUS INFECTION; DISEASE SURVEILLANCE; GRAFT RECIPIENT; GROUPS BY AGE; HEALTH CARE FACILITY; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; INTERNET; MEDICAL PRACTICE; MEDICAL RESEARCH; MYCOSIS; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; TREATMENT DURATION; VARICELLA ZOSTER VIRUS;

ADULT; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; ASIA; AUSTRALIA; CANDIDA; CANDIDIASIS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEALTH CARE SURVEYS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; LATIN AMERICA; MIDDLE EAST; NORTH AMERICA; SIMPLEXVIRUS; SOUTH AFRICA; TRANSPLANTATION, HOMOLOGOUS; WORLD HEALTH;

EID: 79954612431     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.026     Document Type: Article

References (13)

1. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
2. Bowden R.A., Ljungman P., Paya C.V. Transplant Infections 2003, Lippincott Williams & Wilkins, Philadelphia, PA.
3. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
4. Zaia J.A., Gallez-Hawkins G.M., Tegtmeier B.R., et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997, 176:782-785.
5. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545-1552.
6. Pagano L., Caira M., Nosari A., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007, 45:1161-1170.
7. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000, 6:659-713. 715; 717-627; quiz 729-633.
8. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
9. Fraser G.A., Walker Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004, 10:287-297.
10. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009, 44:453-455.
11. Erard V., Wald A., Corey L., Leisenring W.M., Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007, 196:266-270.
12. Peggs K.S., Preiser W., Kottaridis P.D., et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000, 111:782-790.
13. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.